On July 30, 2024, Onconetix Inc. received a letter from Nasdaq stating that its acquisition of Proteomedix AG results in a Change of Control, requiring compliance with initial listing criteria including a minimum share price of $4.00, while also proposing a reverse stock split to help meet Nasdaq's listing requirements.